<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01988831</url>
  </required_header>
  <id_info>
    <org_study_id>HUG-MEL-BB</org_study_id>
    <nct_id>NCT01988831</nct_id>
  </id_info>
  <brief_title>Efficacy of Propranolol Treatment to Prevent Melanoma Progression</brief_title>
  <official_title>Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to
      an earlier detection of the primary tumour and a better prognosis, but melanoma remains an
      aggressive cancer when it comes to its metastatic stage. Three recent retrospective studies
      compared groups of patients diagnosed with primary melanoma and treated with betablockers for
      another indication to patients who never received betablockers. In these three studies, the
      outcome of the disease is significantly better for people under betablocker treatment with a
      decreased rate of recurrence and a better 5 years survival rate. Here we want to investigate
      the efficacy and the tolerability of an adjuvant treatment with propranolol for patients
      suffering from a primary melanoma with a high risk of recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    We must delay the study for some financial reasons
  </why_stopped>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of propranolol on progression free survival for patients suffering from a primary melanoma with a high risk of recurrence</measure>
    <time_frame>five years</time_frame>
    <description>The efficacy of propranolol treatment will be tested in one interim analysis when the last patient enrolled have reached one year of follow up and one final analysis when the last patient enrolled have reached three years of follow up. The primary endpoint of the study will be the progression of the disease.
We will measure the efficacy of a propranolol treatment on the risk of progression of the disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of serum microRNA profile as a predictor for recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>We will investigate the microRNA profile in the serum of patients of both groups during the whole study to identify biomarkers specific for recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>We investigate the impact of propranolol treatment on the 5 years survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Stages III Skin Melanoma</condition>
  <condition>Stages II Skin Melanoma</condition>
  <condition>Stage IB Skin Melanoma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>113 patients will be enrolled in the placebo group with respect to randomization.
Placebo group will be prescribed placebo pills in the same packaging as propranolol treated group.
The frequency and duration of the treatment is the same as propranolol arm. The placebo group will have the same cardiology consultation as propranolol treated group to ensure the respect of blindness.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betablocker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the &quot;Propranolol&quot; Group and treated with propranolol.
The dosage will be determined by the cardiologist as the maximum tolerated dose to a maximum of 160mg/day.
One long acting pill a day until an evidence of disease progression or the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol hydrochloride</intervention_name>
    <description>This intervention apply to Propranolol group</description>
    <arm_group_label>Betablocker</arm_group_label>
    <other_name>Inderal</other_name>
    <other_name>Avlocardyl</other_name>
    <other_name>Hemipralon LP</other_name>
    <other_name>Propranolol EG</other_name>
    <other_name>PROPRANOLOL Ratiopharm</other_name>
    <other_name>Propranolol Teva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient over 18 y.o

          -  Breslow index &gt; 1mm or any Breslow index with ulcerated primary lesion

          -  Melanoma stage AJCC Ib, IIa, IIb, IIc, IIIa, IIIb or IIIc

          -  Able to undergo outpatient treatment

        Exclusion Criteria:

          -  No contra indication for betablockers as defined by the compendium

          -  No clinical evidence of coagulopathy

          -  No unstable angina pectoris

          -  No AV-block II or III without pacemaker

          -  No severe congestive heart failure

          -  No untreated phaeochromocytoma

          -  No severe bradycardia

          -  No severe hypotension

          -  No severe impairment of peripheral arterial circulation

          -  No uncontrolled cardiac arrhythmia

          -  No severe asthma or COPD

          -  No uncontrolled diabetes mellitus

          -  No Angioneurotic edema

          -  No severe Aortic valve stenosis

          -  No severe hypertrophic cardiomyopathy

          -  No severe renal dysfunction

          -  No patients on beta blockers by inclusion

          -  No known adverse reaction to betablockers

          -  No pregnant or lactating patients can be included

          -  No melanoma stage AJCC IV by inclusion

          -  No patients requiring a specific oncological treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique-Anne Le Gal, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital cantonal universitaire de Genève</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital universitaire de Genève</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P. Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med. 2011 Apr 25;171(8):779-81. doi: 10.1001/archinternmed.2011.131.</citation>
    <PMID>21518948</PMID>
  </reference>
  <reference>
    <citation>Lemeshow S, Sørensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, Lesinski GB, Jackson R, Glaser R. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9. doi: 10.1158/1055-9965.EPI-11-0249. Epub 2011 Sep 20.</citation>
    <PMID>21933972</PMID>
  </reference>
  <reference>
    <citation>De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P. Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc. 2013 Nov;88(11):1196-203. doi: 10.1016/j.mayocp.2013.09.001.</citation>
    <PMID>24182700</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Le Gal</investigator_full_name>
    <investigator_title>Associate Physician, PD, MD/PhD</investigator_title>
  </responsible_party>
  <keyword>Malignant melanoma</keyword>
  <keyword>betablocker</keyword>
  <keyword>propranolol</keyword>
  <keyword>interventional</keyword>
  <keyword>prospective</keyword>
  <keyword>adjuvant</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

